All In Biotech

Drug Trial Radar · NCT04006210

Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations

A Multicenter, Randomized, Active-controlled, Double-blind, Double-dummy, Parallel-group Clinical Trial, Investigating the Efficacy, Safety, and Tolerability of Continuous Subcutaneous ND0612 Infusion in Comparison to Oral IR-LD/CD in Subjects With Parkinson's Disease Experiencing Motor Fluctuations (BouNDless)

Last checked: Nov 19, 2026Latest source record: May 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 381 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

381

Actual

Start

Sep 30, 2019

Primary completion

Nov 1, 2022

Study completion Feb 2027

Sponsor

Lead sponsor
NeuroDerm Ltd.Industry
Sponsor type
Industry
First posted
Jul 5, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 30 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-center, randomized, double-blind, double-dummy, active controlled clinical Study. Following a screening period, eligible subjects will be enrolled to an open-label oral IR-LD/CD adjustment period; then an open-label ND0612 conversion period; then after optimization periods subjects will be randomized to receive either ND0612 or its matching Placebo with IR-LD/CD. Subjects can continue to an optional open-label extension period.

Conditions

  • Parkinson's Disease

Interventions

  • ND0612 Solution for SC infusionCombination product

    Levodopa/Carbidopa (LD/CD) solution administered SC via infusion pump

  • Placebo for SC infusionCombination product

    Placebo solution administered SC via infusion pump

  • Oral IR-LD/CDDrug

    Encapsulated LD/CD 100mg/25mg

  • Placebo for Oral IR-LD/CDDrug

    Encapsulated Placebo for LD/CD 100mg/25mg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The change in daily ON time without troublesome dyskinesiaTime frame: Baseline to the end of DBDD Maintenance Period (12 weeks)

Locations

103 sites in 16 countries. Site status is shown where the registry gives one.

  • Xenoscience

    Phoenix, Arizona

  • University of Arkansas for Medical Sciences

    Little Rock, Arkansas

  • Cedar- Sinai Medical Center Department of Neurology

    Los Angeles, California

  • SC3 Research - Reseda

    Reseda, California

  • University of California San Francisco

    San Francisco, California

  • Rocky Mountain Movement Disorders Center

    Englewood, Colorado

  • Hartford Healthcare Chase Family Movement Disorders Center

    Vernon, Connecticut

  • Visionary Investigators Network

    Aventura, Florida

  • Parkinsons Disease and Movement Disorders Center of Boca Raton

    Boca Raton, Florida

  • University of Florida Norman Fixel Institute for Neurological Diseases

    Gainesville, Florida

  • Neurology Associates PA

    Maitland, Florida

  • USF Parkinson's Disease and Movement Disorders Center

    Tampa, Florida

  • Neurology One

    Winter Park, Florida

  • Emory University - Brain Health Center

    Atlanta, Georgia

  • NeuroStudies

    Decatur, Georgia

  • Hawaii Pacific Neuroscience

    Honolulu, Hawaii

  • Rush University Medical Center

    Chicago, Illinois

  • Unity Point Health

    Des Moines, Iowa

  • University of Kansas Medical Center

    Kansas City, Kansas

  • University of Kentucky, Neurology and Movement Disorder

    Lexington, Kentucky

  • Oschner Medical Center

    New Orleans, Louisiana

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • Michigan State University

    East Lansing, Michigan

  • QUEST Research Institute

    Farmington Hills, Michigan

  • Henry Ford West Bloomfield Hospital

    West Bloomfield, Michigan

  • Rutgers-Robert Wood Johnson Medical School

    New Brunswick, New Jersey

  • Weill Cornell Medicine

    New York, New York

  • Mount Sinai Medical center Movement Disorders Center

    New York, New York

  • Duke University

    Durham, North Carolina

  • University of Cincinnati

    Cincinnati, Ohio

  • Cleveland Clinic

    Cleveland, Ohio

  • Corporal Michael J. Crescenz VA Medical Center

    Philadelphia, Pennsylvania

  • Abington Neurological Associates LTD.

    Willow Grove, Pennsylvania

  • Medical University of South Carolina

    Charleston, South Carolina

  • Neurology Consultants of Dallas

    Dallas, Texas

  • University of Vermont Medical Center

    Burlington, Vermont

  • University of Virginia

    Charlottesville, Virginia

  • University of Wisconsin Madison

    Madison, Wisconsin

  • Medical University Innsbruck

    Innsbruck, Austria

  • CHU de Tivoli

    La Louvière, Belgium

Showing 40 of 103 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.